I could easily see a decent percentage of of HDPC patients using Provenge (I absolutely would even w/o P11 data). Obviously the limiting factor is the ability to pay.
If they drop the price a little, you will increase this revenue but decrease the reimbursed revenue.
Tough call.
Would be a very interesting discussion on IV with all the high and mighty types
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.